563 The Effect of Once-Weekly Semaglutide on MACE and Blood Pressure by Race and Ethnicity: SUSTAIN 6 Post Hoc Analysis

In SUSTAIN 6, once-weekly semaglutide added to standard of care significantly reduced major adverse cardiovascular (CV) events (MACE: nonfatal myocardial infarction [MI], nonfatal stroke, CV death) vs placebo over a median 2 years in subjects with type 2 diabetes at high CV risk. This post hoc analysis assessed the effect of semaglutide vs placebo on MACE and blood pressure (BP) by race/ethnicity. Subjects were pooled (semaglutide vs placebo) and analysed by race (Caucasian, Asian, Black/African American, Other) and ethnicity (Hispanic, nonHispanic). Time-to-event data were analysed using unstratified Cox models with pooled treatment and race/ethnicity as subgroup. Estimated treatment differences (ETDs) for change from baseline in BP were from mixed models for repeated measurements with interaction of subgroup, treatment and baseline value as covariate. In total, 3297 subjects were randomised. Hazard ratios for MACE were <1 for all subgroups except CV death (1.01) and nonfatal MI (1.37) in Black/African Americans, and CV death (1.00) in nonHispanics. ETDs for change from baseline in systolic and diastolic BP (SBP and DBP) favoured semaglutide vs placebo in most subgroups except SBP in Black/African Americans, DBP in Caucasians and DBP in nonHispanics, in which the ETDs, respectively, were 4.47, 0.36 and 0.16 mmHg. Interaction p-values for effect of race/ethnicity on the semaglutide treatment effect vs placebo were nonsignificant (p>0.05) for all MACE and BP assessments, except SBP by race (p=0.0008). To conclude, there was no heterogeneity in the effect of semaglutide vs placebo on MACE and BP in race and ethnicity subgroups of SUSTAIN 6.